Abbisko Therapeutics - 上海和誉生物医药科技有限公司-LIST

Press Releases

Abbisko Therapeutics Receives CDE Approval to Initiate a Registrational Study of Irpagratinib (ABSK011) in patients with Hepatocellular Carcinoma

Dec 17, 2024

2024 ASH Oral Presentation——Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

Dec 09, 2024

First Patient Dosed in Phase II Clinical Study of ABSK043, an Oral PD-L1 Small-Molecule Inhibitor, in Combination with Furmonertinib in Patients with Non-Small Cell Lung Cancer (NSCLC)

Dec 11, 2024

ESMO Asia 2024: Oral presentation by Abbisko Therapeutics on updated results from a phase 1 study of ABSK043, an oral PD-L1 inhibitor.

Dec 06, 2024

Abbisko Therapeutics Announces U.S. FDA IND Clearance for ABSK131, a Novel PRMT5*MTA Inhibitor

Dec 03, 2024

First-Patient Dosed in Gastric Cancer in Phase II Clinical Study Evaluating ABSK043, an Oral PD-L1 Inhibitor, in Combination with ABSK061, an Oral FGFR2/3 Inhibitor, for Solid Tumors

Nov 22, 2024

ACoP 2024 ——Abbisko Therapeutics presents results on model-informed dose selection for pimicotinib (ABSK021)

Nov 13, 2024

Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

Nov 12, 2024

2024 ASH Oral Presentation——Abbisko to present preliminary phase 2 study results of pimicotinib for the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting

Nov 08, 2024

Abbisko Therapeutics to present updated results from a phase 1 study of oral PD-L1 inhibitor ABSK043 at ESMO Asia Congress 2024

Nov 07, 2024

Abbisko presented preclinical research results of its PRMT5* MTA and oral KRASG12D programs at the 36th International Molecular Targets and Cancer Treatment Conference (EORTC-NCI-AACR)

Oct 24, 2024

2024 ACoP——Abbisko will present the model-informed dose selection results for Pimicotinib (ABSK021)

Oct 17, 2024

Abbisko Therapeutics has published Phase III study design of Pimicotinib in Future Oncology

Oct 11, 2024

Clinical Trial of Next-Generation EGFR Inhibitor ABK3376, Co-developed by Abbisko Therapeutics and Allist Pharmaceuticals, Approved by NMPA

Sep 25, 2024

Abbisko awarded Best Poster Award at ESMO Congress 2024

Sep 19, 2024

Abbisko Therapeutics Presents Updated Clinical Progress on Irpagratinib and Pimicotinib at European Society for Medical Oncology (ESMO) 2024

Sep 18, 2024

Abbisko Therapeutics will present the latest clinical results of Irpagratinib at the 2024 ESMO Congress

Aug 01, 2024

Abbisko Therapeutics announced a positive profit alert for the first half of 2024

Jul 11, 2024

2024 ESMO-GI | Abbisko Therapeutics presents new phase II clinical data of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma

Jun 28, 2024

Abbisko and Allist Pharmaceuticals Jointly Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer

May 09, 2024

Abbisko Therapeutics Completes Dosing of the First Patient in the Phase II Clinical Trial for ABSK011 in Combination with an Anti-PD-L1 Antibody

Feb 08, 2022

View all

we discover and develop first-in-class and best-in-class therapies

to address critical unmet needs for cancer patients in China and globally

Media

Bioworld: Abbisko’s pimicotinib meets endpoints in phase III

Nov 13, 2024

PharmaBoardroom interviews Dr. Xu Yaochang, the founder and CEO of Abbisko

Jul 17, 2024

Bioworld: Abbisko out-licenses pimicotinib to Merck KGaA in $605M deal

Dec 12, 2023

Endpoints: Abbisko signs $70M upfront deal with Merck KGaA for PhIII cancer drug

Dec 05, 2023

FierceBiotech:Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront

Dec 05, 2023

View all